RenovoRx, Inc.
RNXT
NASDAQ·Healthcare·Biotechnology·Mkt cap $107.7M
$2.39
▲ +0.84%
P/E
-15.93
Mkt Cap
$107.7M
52-Wk Range
$0.70–$2.59
52-Week Range
$0.70 - $2.59
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 109.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Average volatility.
Growth
Strong growth ahead
Value
Deep value opportunity - significant discount to sector peers
Momentum
Hot
+174.1% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying RNXT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 12, 2026
Reported EPS of -$0.05 vs -$0.07 consensus (+31.0% surprise). Revenue of $909.0K vs $703.8K expected (+29.2%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+31.0%
Revenue trend · last 2Q
—
+115%
Q1 26
Q2 26
$563.0K
$909.0K
Margins · last 2Q
Gross
84.3%
Profit
-320.2%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Ascendiant Capital · Aug 28, 2026
vs Industry
How RNXT stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.